FDA Fast Track Therapy Targets HER2-Mutated NSCLC: AACR 2025
Promising new data emerged on zongertinib, an investigational oral therapy targeting HER2 mutations in advanced non-small cell lung cancer (NSCLC), was presented at the AACR Annual Meeting 2025 in Chicago.